Alectinib, a 2nd-generation anaplastic lymphoma kinase–tyrosine kinase inhibitor (ALK-TKI), is an established 1st-line therapy for advanced ALK fusion gene–positive non–small cell lung cancer (NSCLC). This evidence concerns the gene ALK and lung cancer.